For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results this Thursday after market close. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations ...

Here we are approaching an important event, namely October 30, when Gilead will announce its results for the third quarter of 2025. Since my last article, its stock price has hit new 52-week highs. On ...

Continued strength in the HIV portfolio driven by flagship drugs Biktarvy and Descovy, bolstered by FDA approval of long-acting injectable PrEP medication, lenacapavir (Yeztugo). Growth in HIV sales ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q3 CY2025, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year ...

The MarketWatch News Department was not involved in the creation of this content. Groups welcome reversal of Gilead's price gouging decision that would have resulted in fewer people with HIV getting ...

In recent weeks, Gilead Sciences announced Health Canada's conditional approval of LYVDELZI (seladelpar) for primary biliary cholangitis, and presented new positive clinical data across its liver ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine ...

Fintel reports that on October 31, 2025, Needham reiterated coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy recommendation. Analyst Price Forecast Suggests 8.29% Upside As of October 30, 2025, ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $147 from $143 and keeps an Overweight rating on the shares. Gilead’s FY25 guidance for its new Yeztugo HIV PReP ...

Gilead Sciences Inc.’s stock fell, then reversed those losses in after-hours trade Thursday, after the drug company posted weaker-than-expected second-quarter profit and tweaked its guidance. Back To ...